PMC:1283364 / 56890-57135 JSONTXT 5 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T12134 0-245 sentence denotes However, it has been noted that deletion of the Fc receptor (the primary receptor for microglial opsinization of antibody–antigen complexes) in APP transgenic mouse models has no impact on the effectiveness of antibody-mediated therapy [56,57].
T12135 1-8 RB denotes However
T12137 8-10 , denotes ,
T12138 10-12 PRP denotes it
T12139 13-16 VBZ denotes has
T12140 17-21 VBN denotes been
T12136 22-27 VBN denotes noted
T12141 28-32 IN denotes that
T12143 33-41 NN denotes deletion
T12144 42-44 IN denotes of
T12145 45-48 DT denotes the
T12147 49-51 NN denotes Fc
T12146 52-60 NN denotes receptor
T12148 61-62 -LRB- denotes (
T12149 62-65 DT denotes the
T12151 66-73 JJ denotes primary
T12150 74-82 NN denotes receptor
T12152 83-86 IN denotes for
T12153 87-97 JJ denotes microglial
T12154 98-110 NN denotes opsinization
T12155 111-113 IN denotes of
T12156 114-122 NN denotes antibody
T12158 122-123 HYPH denotes
T12157 123-130 NN denotes antigen
T12159 131-140 NNS denotes complexes
T12160 140-141 -RRB- denotes )
T12161 142-144 IN denotes in
T12162 145-148 NN denotes APP
T12163 149-159 JJ denotes transgenic
T12165 160-165 NN denotes mouse
T12164 166-172 NNS denotes models
T12142 173-176 VBZ denotes has
T12166 177-179 DT denotes no
T12167 180-186 NN denotes impact
T12168 187-189 IN denotes on
T12169 190-193 DT denotes the
T12170 194-207 NN denotes effectiveness
T12171 208-210 IN denotes of
T12172 211-219 NN denotes antibody
T12174 219-220 HYPH denotes -
T12173 220-228 VBN denotes mediated
T12175 229-236 NN denotes therapy
T12176 237-238 -LRB- denotes [
T12178 238-240 CD denotes 56
T12179 240-241 , denotes ,
T12177 241-243 CD denotes 57
T12180 243-244 -RRB- denotes ]
T12181 244-245 . denotes .
R8469 T12135 T12136 advmod However,noted
R8471 T12137 T12136 punct ", ",noted
R8472 T12138 T12136 nsubjpass it,noted
R8473 T12139 T12136 aux has,noted
R8475 T12140 T12136 auxpass been,noted
R8476 T12141 T12142 mark that,has
R8478 T12142 T12136 ccomp has,noted
R8479 T12143 T12142 nsubj deletion,has
R8480 T12144 T12143 prep of,deletion
R8482 T12145 T12146 det the,receptor
R8483 T12146 T12144 pobj receptor,of
R8484 T12147 T12146 compound Fc,receptor
R8485 T12148 T12146 punct (,receptor
R8486 T12149 T12150 det the,receptor
R8488 T12150 T12146 appos receptor,receptor
R8489 T12151 T12150 amod primary,receptor
R8490 T12152 T12150 prep for,receptor
R8492 T12153 T12154 amod microglial,opsinization
R8493 T12154 T12152 pobj opsinization,for
R8494 T12155 T12154 prep of,opsinization
R8496 T12156 T12157 compound antibody,antigen
R8497 T12157 T12159 compound antigen,complexes
R8498 T12158 T12157 punct –,antigen
R8500 T12159 T12155 pobj complexes,of
R8501 T12160 T12143 punct ),deletion
R8503 T12161 T12143 prep in,deletion
R8504 T12162 T12163 npadvmod APP,transgenic
R8505 T12163 T12164 amod transgenic,models
R8507 T12164 T12161 pobj models,in
R8508 T12165 T12164 compound mouse,models
R8509 T12166 T12167 det no,impact
R8511 T12167 T12142 dobj impact,has
R8512 T12168 T12167 prep on,impact
R8514 T12169 T12170 det the,effectiveness
R8515 T12170 T12168 pobj effectiveness,on
R8516 T12171 T12170 prep of,effectiveness
R8518 T12172 T12173 npadvmod antibody,mediated
R8521 T12173 T12175 amod mediated,therapy
R8523 T12174 T12173 punct -,mediated
R8524 T12175 T12171 pobj therapy,of
R8525 T12176 T12177 punct [,57
R8526 T12177 T12142 parataxis 57,has
R8528 T12178 T12177 nummod 56,57
R8529 T12179 T12177 punct ",",57
R8530 T12180 T12177 punct ],57
R8532 T12181 T12136 punct .,noted